Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 0.84 million shares were traded. BHC stock price reached its highest trading level at $6.145 during the session, while it also had its lowest trading level at $6.04.
Ratios:
For a deeper understanding of Bausch Health Companies Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.30 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.13. For the most recent quarter (mrq), Quick Ratio is recorded 0.98 and its Current Ratio is at 1.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for the company, Piper Sandler on August 02, 2024, Downgraded its rating to Underweight and sets its target price to $3 from $9 previously.
On July 10, 2024, Raymond James started tracking the stock assigning a Mkt Perform rating and target price of $8.
Jefferies Upgraded its Hold to Buy on September 20, 2023, whereas the target price for the stock was revised from $9 to $16.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 08 ’25 when Carson Seana sold 13,370 shares for $7.31 per share. The transaction valued at 97,735 led to the insider holds 499,585 shares of the business.
Carson Seana bought 13,370 shares of BHC for $97,735 on Sep 08 ’25. On Aug 21 ’25, another insider, Lee Frank D., who serves as the Director of the company, sold 15,912 shares for $7.66 each. As a result, the insider received 121,886 and left with 73,795 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BHC now has a Market Capitalization of 2259418880 and an Enterprise Value of 23181418496. As of this moment, Bausch’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.33, and their Forward P/E ratio for the next fiscal year is 1.47. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 12.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.23. Its current Enterprise Value per Revenue stands at 2.352 whereas that against EBITDA is 7.392.
Stock Price History:
The Beta on a monthly basis for BHC is 0.47, which has changed by -0.2777778 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, BHC has reached a high of $9.85, while it has fallen to a 52-week low of $4.25. The 50-Day Moving Average of the stock is -11.33%, while the 200-Day Moving Average is calculated to be -4.67%.
Shares Statistics:
For the past three months, BHC has traded an average of 2.56M shares per day and 1331860 over the past ten days. A total of 369.75M shares are outstanding, with a floating share count of 327.36M. Insiders hold about 11.48% of the company’s shares, while institutions hold 67.62% stake in the company. Shares short for BHC as of 1759190400 were 7705899 with a Short Ratio of 3.01, compared to 1756425600 on 8256861. Therefore, it implies a Short% of Shares Outstanding of 7705899 and a Short% of Float of 2.25.
Earnings Estimates
A detailed examination of Bausch Health Companies Inc (BHC) is currently in progress, with 4.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $1.18, with high estimates of $1.34 and low estimates of $0.96.
Analysts are recommending an EPS of between $3.97 and $2.94 for the fiscal current year, implying an average EPS of $3.66. EPS for the following year is $4.26, with 6.0 analysts recommending between $4.85 and $3.65.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $2.62B this quarter.It ranges from a high estimate of $2.64B to a low estimate of $2.6B. As of . The current estimate, Bausch Health Companies Inc’s year-ago sales were $2.51BFor the next quarter, 5 analysts are estimating revenue of $2.71B. There is a high estimate of $2.77B for the next quarter, whereas the lowest estimate is $2.67B.
A total of 6 analysts have provided revenue estimates for BHC’s current fiscal year. The highest revenue estimate was $10.18B, while the lowest revenue estimate was $10.04B, resulting in an average revenue estimate of $10.1B. In the same quarter a year ago, actual revenue was $9.62BBased on 6 analysts’ estimates, the company’s revenue will be $10.4B in the next fiscal year. The high estimate is $10.7B and the low estimate is $9.98B.
